Literature DB >> 18492770

The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance.

Muhammad A Abdul-Ghani1, Masafumi Matsuda, Rucha Jani, Christopher P Jenkinson, Dawn K Coletta, Kohei Kaku, Ralph A DeFronzo.   

Abstract

To assess the relationship between the fasting plasma glucose (FPG) concentration and insulin secretion in normal glucose tolerance (NGT) and impaired glucose tolerance (IGT) subjects, 531 nondiabetic subjects with NGT (n = 293) and IGT (n = 238; 310 Japanese and 232 Mexican Americans) received an oral glucose tolerance test (OGTT) with measurement of plasma glucose, insulin, and C-peptide every 30 min. The insulin secretion rate was determined by plasma C-peptide deconvolution. Insulin sensitivity (Matsuda index) was measured from plasma insulin and glucose concentrations. The insulin secretion/insulin resistance (IS/IR) or disposition index was calculated as DeltaISR/DeltaG / IR. As FPG increased in NGT subjects, the IS/IR index declined exponentially over the range of FPG from 70 to 125 mg/dl. The relationship between the IS/IR index and FPG was best fit with the equation: 28.8 exp(-0.036 FPG). For every 28 mg/dl increase in FPG, the IS/IR index declined by 63%. A similar relationship between IS/IR index and FPG was observed in IGT. However, the decay constant was lower than in NGT. The IS/IR index for early-phase insulin secretion (0-30 min) was correlated with the increase in FPG in both NGT and IGT (r = -0.43, P < 0.0001 and r = -0.20, P = 0.001, respectively). However, the correlation between late-phase insulin secretion (60-120 min) and FPG was not significant. In conclusion, small increments in FPG, within the "normal" range, are associated with a marked decline in glucose-stimulated insulin secretion and the decrease in insulin secretion with increasing FPG is greater in subjects with NGT than IGT and primarily is due to a decline in early-phase insulin secretion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18492770      PMCID: PMC4043181          DOI: 10.1152/ajpendo.00674.2007

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  41 in total

Review 1.  Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes.

Authors:  S E Kahn
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

2.  Acute hyperglycemia alters the ability of the normal beta-cell to sense and respond to glucose.

Authors:  Jürgen Meyer; Jeppe Sturis; Martin Katschinski; Rudolf Arnold; Burkhard Göke; Maria M Byrne
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-04       Impact factor: 4.310

3.  Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance.

Authors:  C Weyer; C Bogardus; R E Pratley
Journal:  Diabetes       Date:  1999-11       Impact factor: 9.461

4.  Decrease in beta-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig.

Authors:  L L Kjems; B M Kirby; E M Welsh; J D Veldhuis; M Straume; S S McIntyre; D Yang; P Lefèbvre; P C Butler
Journal:  Diabetes       Date:  2001-09       Impact factor: 9.461

5.  Effect of acute hyperglycemia on insulin secretion in humans.

Authors:  Elena Toschi; Stefania Camastra; Anna Maria Sironi; Antonio Masoni; Amalia Gastaldelli; Andrea Mari; Ele Ferrannini; Andrea Natali
Journal:  Diabetes       Date:  2002-02       Impact factor: 9.461

6.  Disturbances in beta-cell function in impaired fasting glycemia.

Authors:  Timon W van Haeften; Walkyria Pimenta; Asimina Mitrakou; Mary Korytkowski; Trond Jenssen; Hannele Yki-Jarvinen; John E Gerich
Journal:  Diabetes       Date:  2002-02       Impact factor: 9.461

7.  Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response.

Authors:  S D Mittelman; G W Van Citters; S P Kim; D A Davis; M K Dea; M Hamilton-Wessler; R N Bergman
Journal:  Diabetes       Date:  2000-12       Impact factor: 9.461

8.  What is the best predictor of future type 2 diabetes?

Authors:  Muhammad A Abdul-Ghani; Ken Williams; Ralph A DeFronzo; Michael Stern
Journal:  Diabetes Care       Date:  2007-03-23       Impact factor: 19.112

Review 9.  The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes.

Authors:  R N Bergman; D T Finegood; S E Kahn
Journal:  Eur J Clin Invest       Date:  2002-06       Impact factor: 4.686

10.  The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study.

Authors:  David W Dunstan; Paul Z Zimmet; Timothy A Welborn; Maximilian P De Courten; Adrian J Cameron; Richard A Sicree; Terry Dwyer; Stephen Colagiuri; Damien Jolley; Matthew Knuiman; Robert Atkins; Jonathan E Shaw
Journal:  Diabetes Care       Date:  2002-05       Impact factor: 19.112

View more
  30 in total

Review 1.  Treatment of prediabetes.

Authors:  Mustafa Kanat; Ralph A DeFronzo; Muhammad A Abdul-Ghani
Journal:  World J Diabetes       Date:  2015-09-25

2.  Impaired Insulin Action Is Associated With Increased Glucagon Concentrations in Nondiabetic Humans.

Authors:  Anu Sharma; Ron T Varghese; Meera Shah; Chiara Dalla Man; Claudio Cobelli; Robert A Rizza; Kent R Bailey; Adrian Vella
Journal:  J Clin Endocrinol Metab       Date:  2018-01-01       Impact factor: 5.958

3.  A concerted decline in insulin secretion and action occurs across the spectrum of fasting and postchallenge glucose concentrations.

Authors:  Airani Sathananthan; Chiara Dalla Man; Alan R Zinsmeister; Michael Camilleri; Richard J Rodeheffer; Gianna Toffolo; Claudio Cobelli; Robert A Rizza; Adrian Vella
Journal:  Clin Endocrinol (Oxf)       Date:  2012-02       Impact factor: 3.478

4.  Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study.

Authors:  Muhammad A Abdul-Ghani; Valeriya Lyssenko; Tiinamaija Tuomi; Ralph A DeFronzo; Leif Groop
Journal:  Diabetes Care       Date:  2008-11-18       Impact factor: 19.112

5.  Minimal contribution of fasting hyperglycemia to the incidence of type 2 diabetes in subjects with normal 2-h plasma glucose.

Authors:  Muhammad A Abdul-Ghani; Michael P Stern; Valeriya Lyssenko; Tiinamaija Tuomi; Leif Groop; Ralph A Defronzo
Journal:  Diabetes Care       Date:  2009-12-10       Impact factor: 17.152

6.  Early insulin secretory dysfunction in korean prediabetic subjects: should we change the criteria for "prediabetes?".

Authors:  Chul-Hee Kim
Journal:  Korean Diabetes J       Date:  2010-06-30

7.  The relationship between {beta}-cell function and glycated hemoglobin: results from the veterans administration genetic epidemiology study.

Authors:  Mustafa Kanat; Diedre Winnier; Luke Norton; Nazik Arar; Chris Jenkinson; Ralph A Defronzo; Muhammad A Abdul-Ghani
Journal:  Diabetes Care       Date:  2011-02-23       Impact factor: 19.112

8.  Favourable metabolic effects of a eucaloric lower-carbohydrate diet in women with PCOS.

Authors:  Barbara A Gower; Paula C Chandler-Laney; Fernando Ovalle; Laura Lee Goree; Ricardo Azziz; Renee A Desmond; Wesley M Granger; Amy M Goss; G Wright Bates
Journal:  Clin Endocrinol (Oxf)       Date:  2013-05-20       Impact factor: 3.478

Review 9.  Pathophysiology of prediabetes.

Authors:  Muhammad A Abdul-Ghani; Ralph A DeFronzo
Journal:  Curr Diab Rep       Date:  2009-06       Impact factor: 4.810

Review 10.  Plasma glucose concentration and prediction of future risk of type 2 diabetes.

Authors:  Muhammad A Abdul-Ghani; Ralph A DeFronzo
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.